These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3006711)

  • 1. Metabolism of protein conjugate of desacetyl-alacepril and its effect on angiotensin converting enzyme in renal hypertensive rats.
    Matsumoto K; Nambu K; Fujii T; Takeyama K; Miyazaki H; Hashimoto M
    Arzneimittelforschung; 1986; 36(1):52-4. PubMed ID: 3006711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats.
    Nambu K; Matsumoto K; Takeyama K; Hosoki K; Miyazaki H; Hashimoto M
    Arzneimittelforschung; 1986; 36(1):47-51. PubMed ID: 3006710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and metabolism of the novel antihypertensive agent alacepril in rats.
    Matsumoto K; Miyazaki H; Fujii T; Yoshida K; Amejima H; Hashimoto M
    Arzneimittelforschung; 1986; 36(1):40-6. PubMed ID: 3513776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
    Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
    Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the novel orally active angiotensin converting enzyme inhibitor alacepril on cardiovascular system in experimental animals.
    Takeyama K; Minato H; Nakatsuji K; Suzuki H; Nose I; Oka M; Hosoki K; Hatano N; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):69-73. PubMed ID: 3513779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
    Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
    Arzneimittelforschung; 1985; 35(10):1507-12. PubMed ID: 3000390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive mechanism of alacepril: effect on norepinephrine-induced vasoconstrictive response in vitro and in vivo.
    Takeyama K; Minato H; Ikeno A; Hosoki K; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):74-7. PubMed ID: 3513780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of alacepril on renin-angiotensin-aldosterone system and kallikrein-kinin-prostaglandin system in experimental animals.
    Hosoki K; Takeyama K; Minato H; Fukuya F; Kawahara S; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):77-83. PubMed ID: 3006712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of the new oral angiotensin converting enzyme inhibitor 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (Alacepril) in essential hypertension.
    Mizuno K; Hashimoto S; Kunii N; Tani M; Niimura S; Yabe R; Watari H; Fukuchi S
    Res Commun Chem Pathol Pharmacol; 1985 Aug; 49(2):175-87. PubMed ID: 2997886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
    Matsuno Y; Hori H; Oka M; Nakamura H; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):62-8. PubMed ID: 3513778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
    Windt WA; Prakash J; Kok RJ; Moolenaar F; Kluppel CA; de Zeeuw D; van Dokkum RP; Henning RH
    J Renin Angiotensin Aldosterone Syst; 2004 Dec; 5(4):197-202. PubMed ID: 15803438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive mechanism of alacepril. Effects of its metabolites on the peripheral sympathetic nervous system.
    Minato H; Hosoki K; Hayashi K; Sawayama T; Kadokawa T; Hashimoto M
    Arzneimittelforschung; 1989 Mar; 39(3):319-24. PubMed ID: 2547387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Syntheses of [prolyl-U-14C]alacepril and its related compounds].
    Kagemoto A; Nakao M; Negoro T; Sekine Y; Hashimoto M
    Radioisotopes; 1985 Aug; 34(8):408-13. PubMed ID: 3906779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
    Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T
    Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE inhibition restores the vasodilator potency of the endothelium-derived relaxing factor, L-S-nitrosocysteine, in conscious Spontaneously Hypertensive rats.
    Lewis SJ; Hashmi-Hill MP; Owen JR; Sandock K; Robertson TP; Bates JN
    Vascul Pharmacol; 2006 Jun; 44(6):491-507. PubMed ID: 16713366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.
    Junot C; Nicolet L; Ezan E; Gonzales MF; Menard J; Azizi M
    J Pharmacol Exp Ther; 1999 Dec; 291(3):982-7. PubMed ID: 10565814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
    J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure.
    Nonoguchi H; Kiyama S; Kitamura K; Naruse M; Tomita M; Tazoe N; Tajiri M; Nakayama Y; Kohda Y; Inoue T; Tomita K
    Hypertens Res; 2008 Jan; 31(1):29-36. PubMed ID: 18360015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme.
    Kok RJ; Grijpstra F; Walthuis RB; Moolenaar F; de Zeeuw D; Meijer DK
    J Pharmacol Exp Ther; 1999 Jan; 288(1):281-5. PubMed ID: 9862782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.